Central Laboratory of Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Mol Biol Rep. 2013 Feb;40(2):1135-44. doi: 10.1007/s11033-012-2154-2. Epub 2012 Oct 12.
Adiponectin produced by adipose tissue, which is involved in complex diseases related to obesity, such as cancer. Genetic variations in ADIPOQ are thought to influence the activity of adiponectin, thus relating to cancer occurrence. However, epidemiological results were inconsistent. To examine this controversy, we assessed reported studies of association between ADIPOQ polymorphisms and cancer risk. Relevant studies were selected by PUBMED, EMBASE update to January 12th, 2012. According to the acceptance and exclusion criteria, 15 studies involved three polymorphisms (rs266729, rs2241766, rs1501299) of ADIPOQ were included. Summary odds ratio (ORs) and 95 % confidence intervals (CIs) were calculated using random-effect or fixed-effect models based on the heterogeneity of included studies. A total of 15 case-control studies related rs266729 (5,615 cases and 6,425 controls), rs2241766 (5,318 cases and 6,118 controls) and rs1501299 (3,751 cases and 5,104 controls) were included to analyze the ADIPOQ polymorphisms and cancer risk. For rs1501299, T allele was associated with decreased cancer risk. In addition, cancer type subgroup analysis revealed T allele was associated with decreased colorectal and prostate cancer risk. Ethnicity subgroup analysis observed a decreased risk in both Asian and Caucasian descendents. As to rs2241766, a borderline decreased cancer risk was observed. This meta-analysis indicated T allele of rs1501299 was an obvious protection factor for cancer risk, and G allele of rs2241766 was a potential protection factor for cancer risk, especially in Caucasian descendents. Further studies should be performed to clarify the roles of ADIPOQ polymorphisms in the cancer risk.
脂肪组织产生的脂联素与肥胖相关的复杂疾病有关，如癌症。ADIPOQ 的遗传变异被认为会影响脂联素的活性，从而与癌症的发生有关。然而，流行病学研究结果并不一致。为了检验这一争议，我们评估了报告的 ADIPOQ 多态性与癌症风险之间关联的研究。通过 PUBMED、EMBASE 更新至 2012 年 1 月 12 日进行相关研究的选择。根据接受和排除标准，纳入了 15 项涉及 ADIPOQ 三种多态性（rs266729、rs2241766、rs1501299）的研究。根据纳入研究的异质性，采用随机效应或固定效应模型计算汇总比值比（ORs）和 95%置信区间（CIs）。共有 15 项病例对照研究与 rs266729（5615 例和 6425 例对照）、rs2241766（5318 例和 6118 例对照）和 rs1501299（3751 例和 5104 例对照）相关，用于分析 ADIPOQ 多态性与癌症风险。对于 rs1501299，T 等位基因与癌症风险降低相关。此外，癌症类型亚组分析显示 T 等位基因与结直肠癌和前列腺癌风险降低相关。种族亚组分析观察到亚洲和白种人群的风险降低。至于 rs2241766，观察到癌症风险略有降低。这项荟萃分析表明，rs1501299 的 T 等位基因是癌症风险的明显保护因素，rs2241766 的 G 等位基因是癌症风险的潜在保护因素，特别是在白种人群中。应进一步开展研究以阐明 ADIPOQ 多态性在癌症风险中的作用。
